UNRESECTABLE HEPATOCELLULAR CARCINOMA

This study compares two types of radiation therapy for people with liver cancer that cannot be removed by surgery or has come back. One type uses standard X-rays (photons), while the other uses proton beams, which may cause less harm to healthy organs nearby. The goal is to see i…

This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) plus local treatments like chemo injections or radiation works for people with advanced liver cancer that can't be removed by surgery. Researchers will track over 1,100 patients to see how long…

This study is testing a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and co…

This study tests adding bumetanide, a common water pill, to a standard procedure that blocks blood flow to liver tumors. The goal is to find a safe dose and see if it helps control tumor growth. About 30 adults with liver cancer that cannot be removed by surgery will take part.

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapies (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. The trial includes 557 adults whose cancer worsened after initial treatment with atezolizumab and beva…

This study tests whether giving a personalized dose of radiation directly to liver tumors can improve treatment results for people with advanced liver cancer that cannot be removed by surgery. About 42 participants will receive a customized radiation plan based on their individua…

This early-phase study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation procedure can help people with advanced liver cancer that cannot be surgically removed. The trial includes 25 adults whose cancer has spread within the liv…

This study tests a new drug called pevonedistat, given alone or with standard chemotherapy (paclitaxel and carboplatin), in people with advanced bile duct cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors. About 40 adults who hav…

This study watches 300 adults with advanced liver cancer that can't be removed by surgery. All have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine doctor visits to see how well different sec…

This study looked back at medical records of 800 adults with liver cancer that could not be removed by surgery. All patients were treated with lenvatinib-based therapy at six hospitals. The goal was to see how long they lived and how well the treatment worked over three years.